|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differing coping mechanisms, stress level and anorectal physiology in patients with functional constipation显示文摘AIM: To investigate coping mechanisms, constipation symptoms and anorectal physiology in 80 constipated subjects and 18 controls.METHODS: Constipation was diagnosed by Rome Ⅱ criteria.Coping ability and anxiety/depression were assessed by validated questionnaires. Transit time and balloon distension test were performed.RESULTS: 34.5% patients were classified as slow transit type of constipation. The total colonic transit time (56 h vs 10 h, P<0.0001) and rectal sensation including urge sensation (79 mL vs 63 mL, P = 0.019) and maximum tolerable volume (110 mL vs95 mL, P = 0.03) differed in patients and controls. Constipated subjects had significantly higher anxiety and depression scores and lower SF-36 scores in all categories. They also demonstrated higher scores of'monitoring' coping strategy (14+6 vs9+3, P = 0.001),which correlated with the rectal distension sensation (P = 0.005), urge sensation (P=0.002), and maximum tolerable volume (P = 0.035). The less use of blunting strategy predicted slow transit constipation in both univariate (P = 0.01) and multivariate analysis (P = 0.03).CONCLUSION: Defective or ineffective use of coping strategies may be an important etiology in functional constipation and subsequently reflected in abnormal anorectal physiology. | Annie OO Chan Cecilia Cheng Wai Mo Hui Wayne HC Hu Nina YH Wong KF Lam Wai Man Wong Kam Chuen Lai Shiu Kum Lam Benjamin CY Wong | 2005 | World Journal of Gastroenterology2005，11，34： | 92 |
| 2 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 3 | Adenomyoma of the jejunum - a rare cause of gastrointestinal bleeding显示文摘 | Yu HC Lo GH Lai KH | 2008 | J Chin Med Assoe2008，71，2： | 1 |
| 4 | Diagnostic performance of enzyme-linked immunospot assay and whole-blood interferon-γ assay for the diagnosis of extrapulmonary tuberculosis显示文摘 | Lai CC Wang HC | 2011 | J Microbiol Immunol Infect2011，44，： | 1 |
| 5 | Current situations on identification of nontubereulous mycobacteria显示文摘 | Wu TS Lu CC Lai HC | | 0，，01： | 1 |
| 6 | Evaluation of soft-tissue altera- tion around implant-supported single-tooth restoration in the anteri- or maxilla: the pink esthetic score 显示文摘 | Lai HC Zhang ZY Wang F | 2008 | Clin Oral Implants Res2008，19，6： | 1 |
| 7 | Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure显示文摘 | Wang JY Lee LN Lai HC | 2007 | J Antimicrob Chemother2007，59，5： | 1 |
| 8 | Neurotrophie effect of citrus 5-hy- droxy-3,6,7,8,3', 4'-hexamethoxyflavone promotion of neurite out- growth via cAMP/PKA/CREB pathway in PC12 cells 显示文摘 | Lai HC Wu MJ Chen PY | 2011 | PLoS One2011，6，28： | 1 |
| 9 | Development of artemisinin compounds for cancer treatment显示文摘 | Lai HC Singh NP Sasaki T | 2013 | Invest New Drugs2013，31，1： | 1 |
| 10 | Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis 显示文摘 | Lu MC Lai NS Chen HC | 2013 | Clin Exp Immunol2013，171，1： | 1 |
| 11 | Satisfiability and completeness of protocols for electronic negotiations 显示文摘 | Kersten GE Lai HC | 2007 | European Journal of Operational Research2007，180，2： | 1 |
| 12 | Bidirectional regulation of upstream IGF-I/insulin receptor signaling and downstream FOXO1 in cardiomyocytes显示文摘 | Liu TJ Lai HC Ting CT | 2007 | J Endocrinol2007，192，1： | 1 |
| 13 | TBKl-associated protein in endolysosomes ( TAPE ) is an innate immune regulator modulating the TLR3 and TLR4 signaling pathways 显示文摘 | Chang CH Lai LC Cheng HC | 2011 | J Biol Chem2011，286，9： | 1 |
| 14 | Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types显示文摘 | Lai HC Sun CA Yu MH | 1999 | Int J Cancer1999，84，6： | 1 |
| 15 | Insulin-like growth factor- I prevents loss of electrochemical gradient in cardiac muscle mitochondria via activation of PI 3 kinase/Akt pathway显示文摘 | Lai HC Liu TJ Ting CT | 2003 | Mol Cell End~rinol2003，205，12： | 1 |
| 16 | Artemisinin induces apoptosis in human cancer cells 显示文摘 | Singh NP Lai HC | 2004 | Anticancer Res2004，24，4： | 1 |
| 17 | Drug screening identifies niclosamide as an inhibitor of breast cancer stem - like cells显示文摘 | Wang YC Chao TK Lai HC | 2013 | PLoS One2013，188，74： | 1 |
| 18 | Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer 显示文摘 | Lai HC Chu CM Lin YW | 2005 | Gynecol Oncol2005，96，2： | 1 |
| 19 | The significance of human Papillomavirus viral load in Predietion of histologic severity and size of sqaumous intraepithelial lesion of uterine cervix显示文摘 | Sun CA Lai HC Chang CC | 2001 | Gynecol Oncol2001，83，1： | 1 |
| 20 | SFRPI and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway 显示文摘 | Chung MT Lai HC Sytwu HK | 2009 | Gynecol Oncol2009，112，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员